Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. is positioned favorably in the biopharmaceutical sector due to its investigational product candidate, pemvidutide, which has demonstrated significant efficacy in clinical trials by achieving up to 76% liver fat reduction and notable improvements in ALT levels and cT1 biomarkers related to liver inflammation and fibrosis. The drug's favorable tolerability profile compared to existing therapies, combined with its unique dual mechanism of action targeting weight loss and liver function, enhances its potential marketability for both obesity and metabolic-associated liver diseases. Additionally, the FDA's openness to non-invasive endpoints for regulatory approval may expedite pemvidutide's pathway to market, thereby optimizing Altimmune's growth prospects and overall valuation.

Bears say

Altimmune Inc reported a net loss of $23.2 million in the fourth quarter of 2024, indicating significant financial strain as the company continues to develop its product candidate, pemvidutide. Despite pemvidutide's promising clinical results, including an average weight loss of 15.6% in a trial, the overall market adoption of similar therapies has been poor due to issues such as compliance challenges and limited clinical benefits. Furthermore, Altimmune faces multiple risks, including clinical development setbacks, intense competition, and potential challenges around commercialization and funding, all of which contribute to a negative outlook for the company’s stock.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.